The defense takes place

Friday, February 2th, 2024. Time: 13:00 am
At Søndre Skovvej 15, Forskningens Hus, Aalborg Universitetshospital
Place: Auditorium A

After the defense there will be held a reception. All are welcome.

 

PhD main supervisors

• Prof. Tarec Christoffer El-Galaly, Aalborg University Hospital, Denmark

PhD co-supervisors

• Lasse Hjort Jakobsen, Aalborg University Hospital, Denmark

• Prof. Henrik Frederiksen, Odense University Hospital

• Prof. Marianne Tang Severinsen, Aalborg University Hospital, Denmark

Assessment Committee

• Clinical Prof. Søren Schou Olesen, MD, PhD (chair) Aalborg University Hospital, Denmark

• Senior Consultant Morten Kjøbek Lamberts, MD, PhD Herlev-Gentofte Hospital, Denmark

• Prof. Sirpa Marianne Leppä, MD, PhD University of Helsinki, Finland

 

About the PhD thesis

The overall survival for patients with lymphoma has increased in recent decades due to advances in treatment. An increasing number of patients with lymphoma thus are becoming long-term survivors, which entails a risk of late toxicities associated with the chemotherapy regimens used to treat their lymphoma. The aim of this PhD research was to investigate these late toxicities in a real-world setting by establishing associations, risks, and risk factors. This PhD thesis includes four population-based epidemiological cohort studies:

Study I found increased risks of congestive heart failure and cardiovascular diseases in patients with follicular or diffuse large B-cell lymphoma treated with anthracycline-containing immunochemotherapy.

Study II found no increased risk of steroid-induced diabetes mellitus for non-Hodgkin lymphoma patients treated with steroid-containing immunochemotherapy but found a higher risk of insulin use in those with pre-existing diabetes.

Study III established a higher risk of second primary malignancies, driven by non-melanoma skin cancer and myelodysplastic syndrome/acute myeloid leukemia, in aggressive lymphoma patients treated with high-dose therapy and autologous stem cell transplant (HDT-ASCT).

Study IV identified an increased risk of congestive heart failure and cardiovascular diseases in aggressive lymphoma patients treated with HDT-ASCT.

Overall, these studies contribute valuable insights for clinicians in treatment selection, adverse effects screening, and informed decision-making for lymphoma patients.

 

Contact information

You can contact Vibe Joachim Bæch if you have any questions about the defense by clicking here on his e-mail.

Joachim Bæch
E-mail: j.baech@rn.dk
Aalborg University Hospital
Department of Hematology
9000 Aalborg